Regor’s selective approach attracts Roche
For $850m up front Roche gets to challenge Pfizer.
For $850m up front Roche gets to challenge Pfizer.
First-in-human trial initiations reveal four KRAS assets.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
Patients' expression of CEACAM5 might hold the key to activity after all.
The depressed company could use Mylotarg as a stepping stone in AML.
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.